Cost-Effectiveness Analysis of Bevacizumab- Paclitaxel-Carboplatin (PC) Versus PC in First-Line Therapy of Advanced Non-Small Cell Lung Cancer from Patients' Perspective in Vietnam
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2276
https://www.valueinhealthjournal.com/article/S1098-3015(14)04206-5/fulltext
Title :
Cost-Effectiveness Analysis of Bevacizumab- Paclitaxel-Carboplatin (PC) Versus PC in First-Line Therapy of Advanced Non-Small Cell Lung Cancer from Patients' Perspective in Vietnam
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04206-5&doi=10.1016/j.jval.2014.08.2276
First page :
A634
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1734